RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Since Elan took it over, little has been said, so there's little I can say--other than blocking AB aggregation looks like a useful mechanistic goal. From CNS2009:

<<Given the evidence that beta-amyloid’s toxicity blossoms when it clumps together, considerable energy has been devoted to ways of blocking its aggregation into soluble oligomers and/or insoluble fibrils and plaque, the former more important than the latter. The search for a small molecule aggregation-inhibitor is complicated by the fact that beta-amyloid binding is, on the molecular level, a large-scale process. Small molecule inhibitors of AB-aggregation were the core asset of Ellipsis NeuroTherapeutics, acquired by Transition Therapeutics; the lead compound was partnered with Elan in early 2007. Phase II for ELND-005 began at the end of 2007, with treatment lasting for 18 months.>>

NeuroInvestment